JP Morgan Chase’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

JP Morgan Chase’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-30,000	Closed	-$344K	–	6009
2018 Q4	$344K	Buy	+30,000	New	+$373K	﹤0.01%	4324

Other funds holding SGMO

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

AIM

Axiom Investment Management New York $150M AUM

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

JP Morgan Chase's SGMO Position: Q2 2026 in Review

JP Morgan Chase sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 489 shares — an estimated $150 sold.

JP Morgan Chase first reported a position in SGMO in Q2 2013 and held it in 42 quarters. The position peaked at $39.2M in Q2 2021. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

JP Morgan Chase reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
JP Morgan Chase sold 489 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $150.
JP Morgan Chase first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 42 quarters.
JP Morgan Chase's SANGAMO THERAPEUTICS INC position peaked at $39.2M in Q2 2021.
6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.